{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-046158","form_type":"8-K/A","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.213859+00:00","generated_at":"2026-05-30T01:39:05.687851+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Femasys Q3 2024 revenue up 127% to $555K; net loss widens to $5.4M","bullets":["Revenue $554,908 (+127% YoY); first U.S. and international FemaSeed sales recorded.","Net loss $5.4M ($0.24/share) vs $4.0M ($0.26) in Q3 2023; cash $7.6M.","Cash runway expected into July 2025 based on current operating plan.","Partnerships with Boston IVF, Spain distributors; FDA clearance for FemChec; CE Mark for FemVue MINI."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-046158","json":"https://secwatch.observer/filing/0001140361-24-046158.json","markdown":"https://secwatch.observer/filing/0001140361-24-046158.md","text":"https://secwatch.observer/filing/0001140361-24-046158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036124046158/0001140361-24-046158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036124046158/ef20038498_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:39:05.687851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}